Cellectis S.A.
lasme-cel
relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
Countdown
87days
Phase 2 readout · ~ Oct 1, 2026 estimated
What's at stake
Phase 2 trial results for lasme-cel in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) are due ~ Oct 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 6-K
verified 10h ago
“The first interim analysis for the pivotal Phase 2 of the BALLI-01 trial is expected in Q4 2026.”